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Increasing blood pressure has a continuum of adverse risk for cardiovascular events. Traditionally this single measure was used
to determine who to treat and how vigorously. However, estimating absolute risk rather than measurement of a single risk factor
such as blood pressure is a superior method to identify who is most at risk of having an adverse cardiovascular event such as
strokeormyocardialinfarction,andtherefore whowouldmostlikelybeneﬁt fromtherapeutic intervention.Cardiovasculardisease
(CVD) risk calculators must be used to estimate absolute risk in those without overt CVD as physician estimation is unreliable.
Incorporation into usual practice and limitations of the strategy are discussed.
1.Introduction
Physicians treat diseases. For this reason when increasing
blood pressure was recognized as a risk factor for coronary
artery disease and stroke, it was dichotomized into a disease
state “hypertension” and a nondisease state “normotension”
by creating an arbitrary cut point. This cut point has gen-
e r a l l yb e c o m el o w e ro v e rt i m ea se v i d e n c eo fb e n e ﬁ ti n
treating blood pressure levels lower than the contemporary
accepted cut points accumulated. Recognition of other risk
factors such as dyslipidemia, higher risk groups such as the
aged [1, 2], and those with comorbid conditions such as
diabetes [3]h a sl e dt od i ﬀerential treatment thresholds and
target blood pressures resulting in confusing or conﬂicting
guideline recommendations, depending on which peak body
produced them. Is there a simpler way to identify those most
likely to have a major adverse cardiovascular event who do
not have overt disease, and therefore who needs rigorous
therapeutic intervention for their blood pressure and other
CVD risk factors?
2.AbsoluteCardiovascularRisk
Increasing blood pressure has a log-linear relationship with
adverse risk for cardiovascular events [4]. Using this ﬁgure
alone in clinical decisionmaking risks overtreatment (“med-
icalization” where medication adverse events likely to exceed
beneﬁt, and adverse cost-eﬀectiveness) and undertreatment
(failure to act where medication beneﬁt is likely to exceed
adverse events and be cost eﬀective). Estimating absolute
risk, the risk of having an adverse cardiovascular eventover a
speciﬁed period of time (usually 5 or 10 years), is a superior
method to measurement of blood pressure alone to identify
who is most at risk of having a cardiovascular event and
therefore who would most likely beneﬁt from intervention
[5, 6]. It does this because the ﬁgure derived is more holistic,
incorporating other CVD risk factors that explain almost
all risk including blood pressure, and directly estimates
why we treat blood pressure in any population without
CVD, to prevent its onset and complications. Guidelines are
increasingly recognizing the beneﬁt of utilizing absolute risk
scores rather than blood pressure measurements alone [7–
12].
3.CardiovascularDisease RiskCalculators
CVD risk calculators are based on algorithms derived from
observational prospective cohort studies such as the Fram-
ingham study [13, 14]. CVD risk calculators must be used
to estimate absolute risk in those without prior CVD events2 International Journal of Hypertension
as physician estimation is unreliable [15]. Physicians can
reliably estimate relative risk, the risk ofan individual having
a myocardial infarction or stroke relative to others of the
same age and gender. The problem with relative risk is that
by its very nature it excludes the two most important drivers
of CVD risk, age and gender. There are validated algorithms
speciﬁcally derived from hypertensive populations available
[16] but such scores would tend to fragment absolute risk
scores back into their constituent risk factor classiﬁcation
rather than unify and simplify the process. Similarly there
have been many validated algorithms using other than the
“classic” risk factors used in the Framingham risk score (age,
gender, blood pressure, serum cholesterol, smoking status,
and presence of diabetes) but the beneﬁts of this increase in
complexity is marginal.
Absoluterisk scores(ARS)derivedfrom these algorithms
have proven to have good discrimination in their source
population (e.g., Framingham risk score C statistic 0.763
(males), 0.793 (females) [13]) but do have problems in sub-
groups not adequately represented in the study population.
For example, calculators derived from the Framingham risk
score have an upper age limit because no persons over 74
years were included in the study population [17]. Obviously,
from an international perspective, not only subgroups but
whole populations were missing. For example, Australian
aborigines, an important high adverse CVD risk ethnic
minority in Australia, have resisted all attempts to be reliably
and validly incorporated into Australian algorithms derived
from the Framingham risk score [11, 18].
Limitations in ARS use include the following.
(1) It should not be utilized in those with overt CVD.
They are by deﬁnition at high risk and should be
aggressively managed.
(2) Those with target organ damage due to elevated
blood pressure such as left ventricular hypertrophy
and hypertensive retinopathy or nephropathy. Such
individuals have progressed from a risk factor to a
disease state.
(3) Those with blood pressure ≥180/100mmHg.
(4) Those from a non-Caucasian population unless the
risk score utilized has been derived from and/or
validated in this population or has been recalibrated.
Once identiﬁed and the decision has been made to treat
based on absolute risk score, then management reverts to
that of the individual risk factor. The concept of treating
absolute risk per se is supported by clinical trials such as the
HOPE study [19], but the hypothesis needs to be formally
testedinstudiessuchasongoingandplanned“polypill”trials
[20]. This management strategy promises simpler treatment
regimens, lower direct costs, and superior clinical outcomes.
Outside of the “polypill” approach it would give physicians
therapeutic ﬂexibility. If adverse eﬀects prevent drug therapy
of a particular risk factor then intervene on another.
4.Conclusions
Management of persons with elevated blood pressure is best
done through an absolute risk approach including the use of
absolute risk scores. This promises better targeted therapy,
simpler more ﬂexible management regimens, and superior
clinical outcomes.
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